Parabilis Medicines, Inc. (PBLS)
PBLS Stock Price Chart
Explore Parabilis Medicines, Inc. interactive price chart. Choose custom timeframes to analyze PBLS price movements and trends.
PBLS Company Profile
Discover essential business fundamentals and corporate details for Parabilis Medicines, Inc. (PBLS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jun 2026
Employees
145.00
Website
http://www.parabilismed.comCEO
Mathai Mammen
Description
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
PBLS Financial Timeline
Browse a chronological timeline of Parabilis Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.17, while revenue estimate is $16.67m.
Earnings released on 19 May 2026
EPS came in at -$0.88 .
PBLS Stock Performance
Access detailed PBLS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
